Sanctuary Advisors LLC Grows Stock Holdings in Stryker Corporation $SYK

Sanctuary Advisors LLC lifted its position in Stryker Corporation (NYSE:SYK) by 10.8% during the first quarter, Holdings Channel reports. The institutional investor owned 68,329 shares of the medical technology company’s stock after buying an additional 6,672 shares during the quarter. Sanctuary Advisors LLC’s holdings in Stryker were worth $22,452,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of SYK. VanderPol Investments L.L.C. boosted its stake in Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after acquiring an additional 28 shares in the last quarter. KCM Investment Advisors LLC lifted its holdings in shares of Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after purchasing an additional 28 shares during the last quarter. Rossby Financial LCC boosted its position in shares of Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after purchasing an additional 28 shares in the last quarter. Tcfg Wealth Management LLC boosted its position in shares of Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares in the last quarter. Finally, Mechanics Financial Corp grew its stake in Stryker by 1.2% during the 4th quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock worth $864,000 after buying an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 1.7%

Shares of SYK stock opened at $316.46 on Thursday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The firm has a market capitalization of $121.32 billion, a PE ratio of 36.63, a P/E/G ratio of 1.99 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock’s 50-day simple moving average is $311.28 and its 200-day simple moving average is $337.10.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio is presently 40.74%.

Wall Street Analyst Weigh In

A number of research firms have commented on SYK. JPMorgan Chase & Co. decreased their price target on Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Barclays dropped their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a research report on Friday, May 1st. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Finally, Argus set a $370.00 target price on shares of Stryker in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $392.52.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 over the last 90 days. Insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.